Skip to main content

Advertisement

SpringerLink
Log in

Treatment of chronic hepatitis C: Improved combination therapy

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

There has been considerable progress in the treatment of chronic hepatitis C since the first report that interferon (IFN) monotherapy was effective in 1989. Early results were meager, with sustained loss of hepatitis C virus from blood in fewer than 10% of cases. The combination of IFN with the oral nucleoside analogue ribavirin was a major breakthrough in clinical hepatology; it led to dramatic increases in treatment responses, with 30% to 40% of patients clearing virus. Pegylated IFNs that have prolonged activity and can be dosed once a week have now replaced standard IFNs. The combination of pegylated IFN with ribavirin is the new standard of care; it causes sustained loss of virus in more than half of treated patients. Treatment responses continue to be highly dependent on viral genotype. Patients with genotype 1, the most common type in the United States, have a sustained clearance rate of 42% to 46%, whereas those with genotype 2 or 3 have a response rate approaching 80%.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Alter MJ: The epidemiology of acute and chronic hepatitis C. Clin Liver Dis 1997, 1:559–568.

    Article  PubMed  CAS  Google Scholar 

  2. Alter M, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556–562.

    Article  PubMed  CAS  Google Scholar 

  3. Alter MJ, Hadler SC, Judson FN, et al.: Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990, 264:2231–2235.

    Article  PubMed  CAS  Google Scholar 

  4. Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting the future healthcare burden from hepatitis C in the United States. Liver Transpl 2002, in press. The paper uses a validated mathematical model of the natural history of hepatitis C to project the course of infection in the US population in coming decades. A dramatic increase in cases of hepatic decompensation and hepatocellular carcinoma is estimated.

  5. Sànchez-Tapias JM, Barrera JM, Costa J, et al.: Hepatitis C virus infection in patients with nonalcoholic chronic liver disease. Ann Intern Med 1990, 112:921–924.

    PubMed  Google Scholar 

  6. Meyer RA, Gordon SC: Epidemiology of hepatitis C virus infection in a suburban Detroit community. Am J Gastroenterol 1991, 86:1224–1226.

    PubMed  CAS  Google Scholar 

  7. Seeff LB, Buskell-Bales Z, Wright EC, et al.: Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992, 327:1906–1911.

    Article  PubMed  CAS  Google Scholar 

  8. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999, 340:745–750.

    Article  PubMed  CAS  Google Scholar 

  9. Primary Liver Disease of Liver Transplant Recipients 1991 and 1992. The UNOS Scientific Registry [no authors listed]. UNOS Update 1993, 9:27.

  10. Peters M, Davis GL, Dooley JS, et al. The IFN system in acute and chronic viral hepatitis. In Progress in Liver Diseases, vol 8. Edited by Popper H, Schaffner F. New York: Grune and Stratton; 1986:453–467.

    Google Scholar 

  11. Hoofnagle JH, Mullen KD, Jones DB, et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. New Engl J Med 1986, 315:1575–1578.

    Article  PubMed  CAS  Google Scholar 

  12. Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study. N Engl J Med 1989, 321:1501–1506.

    Article  PubMed  CAS  Google Scholar 

  13. DiBisceglie AM, Martin P, Kassianides C, et al.: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-bind, placebo-controlled trial. N Engl J Med 1989, 321:1506–1510.

    Article  CAS  Google Scholar 

  14. Poynard T, Leroy V, Cohard M, et al.: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996, 24:778–789.

    Article  PubMed  CAS  Google Scholar 

  15. McHutchison JG, Gordon S, Schiff ER, et al.: Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial treatment for chronic hepatitis C: results of a U.S. multicenter randomized controlled study. N Engl J Med 1998, 339:1485–1492.

    Article  PubMed  CAS  Google Scholar 

  16. Poynard T, Marcellin P, Lee S, et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998, 352:1426–1432.

    Article  PubMed  CAS  Google Scholar 

  17. Patterson JL, Fernandez-Larson R: Molecular action of ribavirin. Rev Infect Dis 1990, 12:1132–1146.

    Google Scholar 

  18. Crumpacker CS: Overview of ribavirin treatment of infection caused by RNA viruses. In Clinical Applications of Ribavirin. Edited by RA Smith et al. Orlando, FL: Academic Press; 1984:33–38.

    Google Scholar 

  19. Martin J, Navas S, Quiroga JA, et al.: Effects of the ribavirininterferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998, 10:635–644.

    Article  PubMed  CAS  Google Scholar 

  20. Ning Q, Brown D, Parodo J, et al.: Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, and procoagulant activity and preserves TH1 cytokine production, but inhibits TH2 cytokine response. J Immunol 1998, 160:3487–3493.

    PubMed  CAS  Google Scholar 

  21. Cramp ME, Rossol S, Chokshi S, et al.: Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000, 118:346–355.

    Article  PubMed  CAS  Google Scholar 

  22. Reichard O, Andersson J, Schvarcz R, et al.: Ribavirin treatment for chronic hepatitis C. Lancet 1991, 337:1058–1061.

    Article  PubMed  CAS  Google Scholar 

  23. Bodenheimer HC, Lindsay KL, Davis GL, et al.: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997, 26:473–477.

    Article  PubMed  CAS  Google Scholar 

  24. Reichard O, Norkrans G, Fryden A, et al.: Alfa-interferon and ribavirin versus alfa-interferon alone as therapy for chronic hepatitis C-a randomized, double-blind, placebo-controlled study. Lancet 1998, 351:83–87.

    Article  PubMed  CAS  Google Scholar 

  25. McHutchison JG, Poynard T: Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999, 19:57–65.

    PubMed  CAS  Google Scholar 

  26. Schalm SW, Weiland O, Hansen BE, et al.: Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled studies. Gastroenterology 1999, 117:408–413.

    Article  PubMed  CAS  Google Scholar 

  27. Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.

    PubMed  CAS  Google Scholar 

  28. Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875–881.

    PubMed  CAS  Google Scholar 

  29. Poynard T, McHutchison J, Goodman Z, et al.: Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000, 3:211–218.

    Article  Google Scholar 

  30. Davis GL, Lau JYN: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997, 26(suppl):122–127.

    Article  Google Scholar 

  31. Wang YS, Youngster S, Bausch J, et al.: Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000, 39:10634–10640.

    Article  PubMed  CAS  Google Scholar 

  32. Glue P, Fang JW, Rouzier-Panis R, et al.: Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000, 68:556–567.

    Article  PubMed  CAS  Google Scholar 

  33. Xu ZX, Hoffman J, Patel I, Joubert P: Single dose safety/tolerability and pharmacokinetic/pharmacodynamics following administration of ascending doses of pegylated interferon and interferon alfa 2a to healthy subjects [abstract]. Hepatology 1998, 28:702A.

    Article  Google Scholar 

  34. Modi MW, Fulton JS, Buckmann DK, et al.: Clearance of pegylated (40 kDa) interferon alfa-2a is primarily hepatic [abstract]. Hepatology 2000, 32:371A.

    Google Scholar 

  35. Heathcote EJ, Shiffman ML, Cooksley WG, et al.: Peg-interferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000, 343:1673–1680.

    Article  PubMed  CAS  Google Scholar 

  36. Zeuzem S, Feinman SV, Rasenack J, et al.: Peg-interferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000, 343:1666–1672.

    Article  PubMed  CAS  Google Scholar 

  37. Trepo C, Lindsay K, Niederau C, et al.: Pegylated interferon alfa-2b monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C [abstract]. J Hepatol 2000, 32(suppl_2):29A.

    Article  Google Scholar 

  38. Manns MP, McHutchison JG, Gordon S, et al.: Peg-interferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358:958–965.

    Article  PubMed  CAS  Google Scholar 

  39. Fried MW, Shiffman ML, Reddy R, et al.: Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982. Describes the results of treatment with peginterferons in combination with oral ribavirin. This regimens represents the current gold standard for treatment of chronic hepatitis C.

    Article  PubMed  CAS  Google Scholar 

  40. Hadziyannis SJ, Cheinquer H, Morgan T, et al.: Peg-interferon alfa-2a (40KD)(Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, doubleblind, multicentre study examining the effect of duration of treatment and ribavirin dose [abstract]. J Hepatol 2002, 37:536A. An important study that demonstrates the impact of treatment duration and ribavirin dose on SVRs. This study clearly demonstrates that 12 months of treatment with peginterferon plus 1000 to 1200 mg of ribavirin per day is optimal for genotype 1 patients, whereas 6 months of peginterferon with only 800 mg/d of ribavirin is sufficient for genotypes 2 and 3.

    Article  Google Scholar 

  41. Layden JE, Layden TJ: How can mathematics help us understand HCV? Gastroenterology 2001, 120:1546–1549.

    Article  PubMed  CAS  Google Scholar 

  42. Zeuzem S, Herrmann E, Lee JH, et al.: Viral kinetics in patients with chronic hepatitis treated with standard and peg-interferon alfa-2a. Hepatology 2001, 120:1438–1447.

    CAS  Google Scholar 

  43. Davis GL: Utilization of virologic testing in the treatment of chronic hepatitis C. Hepatology 2002, 36:S145-S151.

    Article  PubMed  Google Scholar 

  44. Ferenci P, Shiffman ML, Fried MW, et al.: Early prediction of response to 40 KDa peg-interferon alfa-2a (Pegasys) plus ribavirin in patients with chronic hepatitis C [abstract]. Hepatology 2001, 34:351A.

    Article  CAS  Google Scholar 

  45. Davis GL, Lau JYN, Urdea MS, et al.: Quantitative detection of hepatitis C virus (HCV) RNA by a solid-phase signal amplification method: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994, 19:1337–1341.

    Article  PubMed  CAS  Google Scholar 

  46. Pradat P, Chossegros P, Bailly F, et al.: Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat 2000, 7:203–210.

    Article  PubMed  CAS  Google Scholar 

  47. Martinot-Peignoux M, Le Breton V, Fritsch S, et al.: Assessment of viral loads in patients with chronic hepatitis C with Amplicor HCV Monitor version 1.0, Cobas HCV Monitor version 2.0, and Quantiplex HCV RNA version 2.0 assays. J Clin Microbiol 2000, 38:2722–2725.

    PubMed  CAS  Google Scholar 

  48. Pawlotsky JM, Bouvier-Alias M, Hezode C, et al.: Standardization of hepatitis C virus RNA quantification. Hepatology 2000, 32:654–659.

    Article  PubMed  CAS  Google Scholar 

  49. McHutchison JG, Manns M, Patel K, et al.: Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002, 123:1061–1069.

    Article  PubMed  CAS  Google Scholar 

  50. McHutchison J, Davis GL, Esteban-Mur R, et al.: Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon alfa-2b alone or in combination with ribavirin [abstract]. Hepatology 2001, 34:244A.

    Google Scholar 

  51. Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled study. New Engl J Med 1989, 321:1501–1506.

    Article  PubMed  CAS  Google Scholar 

  52. Cammà C, Giunta M, Chemello L, et al.: Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. Hepatology 1999, 30:801–807.

    Article  PubMed  Google Scholar 

  53. Alberti A, Chemello L, Noventa F, et al.: Therapy of hepatitis C: retreatment with alpha interferon. Hepatology 1997, 26(suppl):137–142.

    Article  Google Scholar 

  54. Davis GL, Esteban-Mur R, Rustgi V, et al.: Recombinant interferon alfa-2b (Intron A) alone or in combination with ribavirin (Rebetol) for retreatment of interferon relapse in chronic hepatitis C. New Engl J Med 1998, 339:1493–1499.

    Article  PubMed  CAS  Google Scholar 

  55. Bellobouno A, Mondazzi L, Tempini S, et al.: Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat 1997, 4:185–191.

    Article  Google Scholar 

  56. Poynard T, McHutchison J, Davis GL, et al.: Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000, 32:1131–1137.

    Article  PubMed  CAS  Google Scholar 

  57. Poynard T, Moussali J, Ratziu V, et al.: Effects of interferon therapy in "non-responder" patients with chronic hepatitis C. J Hepatol 1999, 31:178–183.

    Article  PubMed  Google Scholar 

  58. Shiffman ML, Hofmann CM, Contos MJ, et al.: A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999, 117:1164–1172.

    Article  PubMed  CAS  Google Scholar 

  59. Everson G: Maintenance interferon for chronic hepatitis C: more issues than answers. Hepatology 2000, 32:436–438.

    Article  PubMed  CAS  Google Scholar 

  60. Shiratori Y, Imazeki F, Moriyama M, et al.: Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000, 132:517–524.

    PubMed  CAS  Google Scholar 

  61. Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127:875–881.

    PubMed  CAS  Google Scholar 

  62. Wong JB, McQuillan GM, McHutchison JG, Poynard T: Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000, 90:1562–1569.

    PubMed  CAS  Google Scholar 

  63. Bonkovsky HL, Woolley JM: Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology 1999, 29:264–270.

    Article  PubMed  CAS  Google Scholar 

  64. Ware JE, Bayliss MS, Mannocchia M, Davis GL: Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The International Hepatitis Interventional Therapy Group. Hepatology 1999, 30:550–555.

    Article  PubMed  Google Scholar 

  65. Davis GL, Nelson DR, Reyes G: Future options for the management of hepatitis C. Semin Liver Dis 1999, 19(suppl 1):103–112.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hepatology, Liver Transplantation, Baylor University Medical Center, Baylor Regional Transplant Institute, 3500 Gaston Avenue, 75246, Dallas, TX, USA

    Gary L. Davis MD

Authors
  1. Gary L. Davis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Davis, G.L. Treatment of chronic hepatitis C: Improved combination therapy. Curr hepatitis rep 2, 40–46 (2003). https://doi.org/10.1007/s11901-003-0013-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-003-0013-2

Keywords

Search

Navigation